Independent Study Validates BioNeutral’s Ygiene
In an independent study, BioNeutral’s Ygiene antimicrobial formulation eliminated a particularly dangerous type of mold in record time.
Member Spotlight
Positive Peer Review for Aureon’s Prostate Px+
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
Aureon Featured In TV Segment
Aureon Laboratories, a developer of predictive tests for cancer care, has been featured in a cable television segment produced by the Yonkers Chamber of Commerce.
Clarient Files Registration Agreement With SEC
Clarient has filed a registration statement with the Securities and Exchange Commission on Form S-3 relating to shares of Clarient owned by Safeguard.
SyntheMed Nominated for Frost & Sullivan Award
The Iselin, NJ-based company was recognized for its REPEL-CV Anti-Adhesion Barrier.
CNS Closes $1M Bridge Loan, Completes Clinical Trial Enrollment
The money will allow CNS Response, based in Costa Mesa, Calif., to complete an upcoming depression study.
BioNeutral Ships Mold-Fighting Ogiene-M Formulation
BioNeutral, a life science company that specializes in biohazard neutralization technologies, has started shipping its Ogiene-M formulation to fulfill an agreement between BioNeutral and Mr. Mold.
Clarient Launches New Gene Mutation Test for Lung Cancer
Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
TearLab Wins Silver Medical Design Excellence Award
TearLab Corporation of San Diego announced that its TearLab Osmolarity System has received a Silver 2009 Medical Design Excellence Award.
Correction: Sentinel – Symphony Medical
In last week’s Sentinel, OneMedPlace reported that Symphony Medical had initiated a Phase II clinical trial of their Plexisyl-AF device to treat atrial fibrillation.